<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959345</url>
  </required_header>
  <id_info>
    <org_study_id>2018-001207-37</org_study_id>
    <nct_id>NCT03959345</nct_id>
  </id_info>
  <brief_title>Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia</brief_title>
  <acronym>SAFO</acronym>
  <official_title>Multicenter, Randomised, Open-label Phase III-IV Study to Evaluate the Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: SAFO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miquel Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Bellvitge</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high&#xD;
      morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA)&#xD;
      bacteremia standard treatment was cloxacillin. Previous studies using different therapies and&#xD;
      combination treatment fall to improve survival in these patients.&#xD;
&#xD;
      Aim: to demonstrate the efficacy of the cloxacillin and fosfomycin combination administered&#xD;
      during the first week of treatment, compared with cloxacillin monotherapy in patients with&#xD;
      MSSA bacteremia in treatment success. Methods: A multicentre, superiority, open-label,&#xD;
      randomized, phase IV-III, two-armed parallel (1:1) groups clinical trial. Adult patients with&#xD;
      MSSA bacteremia will be randomized to Combination therapy group: patients will receive&#xD;
      intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment, or&#xD;
      Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration&#xD;
      of 7 days IV treatment. After the first week, antibiotic treatment and duration will be&#xD;
      decided by responsible clinician following clinical practice.&#xD;
&#xD;
      The primary endpoint is the treatment success measured at day 7 of treatment; a composite&#xD;
      endpoint defined by all of the following criteria met after randomization: patient alive at&#xD;
      day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever&#xD;
      resolved at day 7 AND negative blood cultures for S. aureus at day 7.&#xD;
&#xD;
      In case of achieving statistical differences in the primary endpoint, investigators will&#xD;
      perform a hierarchical analysis of the treatment success at Test of Cure visit (TOC, 12 weeks&#xD;
      after randomization), defined by the presence of all of the following: patient alive at TOC&#xD;
      AND no evidence of microbiological treatment failure defined as isolation of S. aureus from&#xD;
      blood culture or other sterile site from day 8 after randomization until TOC.&#xD;
&#xD;
      Investigators have assumed a 74% of treatment success in monotherapy group. Accepting an&#xD;
      alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 183 subjects are necessary in&#xD;
      first group and 183 in the second to find a statistically significant difference of 12%. It&#xD;
      has been anticipated a drop-out rate of 5%.&#xD;
&#xD;
      Discussion: Randomized studies assessing efficacy of different treatment in MSSA bacteremia&#xD;
      are lacking. This study could help to improve knowledge about MSSA bacteremia and whether&#xD;
      combined treatment with cloxacillin and fosfomycin could improve outcomes compared with&#xD;
      standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAFO trial is a multicentre, superiority, open-label, randomized, phase IV-III, two-armed&#xD;
      parallel (1:1) groups clinical trial comparing combination treatment with fosfomycin and&#xD;
      cloxacillin with standard therapy with cloxacillin in adult patients with MSSA bacteremia.&#xD;
&#xD;
      Patients will be randomized to:&#xD;
&#xD;
        -  Standard treatment group: patients will receive intravenous cloxacillin 2g/4h for the&#xD;
           duration of 7 days IV treatment. If creatinine clearance is &lt;30 mL/min cloxacillin will&#xD;
           be administrated at dose of 2g every 6 hours.&#xD;
&#xD;
        -  Combination therapy group: patients will receive intravenous cloxacillin as explained&#xD;
           above and fosfomycin 3 g/6h for the duration of 7 days treatment. In case of renal&#xD;
           failure, fosfomycin will be administrated as follow:&#xD;
&#xD;
      Creatinine clearance (mL/min) Fosfomycin dosage &gt;40 3 g every 6 hours 20-40 3 g every 12&#xD;
      hours 10-20 3g every 24 hours &lt;10 3 g every 48 hours Haemodialysis 3 g after haemodialysis&#xD;
      Continuous renal replacement therapy 3 g every 24h hours&#xD;
&#xD;
      The duration of overall antibiotic treatment and the duration of intravenous treatment will&#xD;
      be determined according to clinical criteria depending on status (complicated or&#xD;
      uncomplicated bacteremia, source of infection) by responsible clinician according with&#xD;
      current guidelines. Patient with complicated bacteremia will receive at least 4-6 week of&#xD;
      antibiotic treatment.&#xD;
&#xD;
      Primary endpoint&#xD;
&#xD;
      Treatment success at day 7 is a composite outcome defined by all of the following criteria&#xD;
      met after randomization:&#xD;
&#xD;
        -  Patient alive at day 7 AND&#xD;
&#xD;
        -  Clinical improvement measured by stable or improved quick SOFA score (compared with&#xD;
           baseline) at day 7 AND&#xD;
&#xD;
        -  Fever resolved at day 7 AND&#xD;
&#xD;
        -  Negative blood cultures for S. aureus at day 7.&#xD;
&#xD;
      In case of statistical differences observed between groups in the primary endpoint,&#xD;
      investigators will perform a hierarchical testing analyzing the treatment success at Test of&#xD;
      Cure (TOC visit, 12 weeks after randomization).&#xD;
&#xD;
      Treatment success at TOC visit is defined by presence of all of the following:&#xD;
&#xD;
        -  Patient alive at TOC;&#xD;
&#xD;
        -  No isolation of MSSA in blood culture or in another sterile site from day 8 until Test&#xD;
           of Cure visit (TOC, 12 weeks after randomisation). In case of patients with prolonged&#xD;
           course of antibiotic treatment (more than 10 weeks), TOC visit will be performed two&#xD;
           weeks after the end of treatment (EOT).&#xD;
&#xD;
      Treatment failure is defined by the presence of one of the following condition: all-cause&#xD;
      mortality at TOC, positive blood cultures at day 7 or later, withdraw of the study because of&#xD;
      adverse events related to study treatment, requirement of an additional MSSA-active&#xD;
      antibiotic until day 7, lacking of clinical improvement at day 7.&#xD;
&#xD;
      Secondary endpoint&#xD;
&#xD;
      Clinical secondary endpoints:&#xD;
&#xD;
        -  To compare all-cause mortality at days 7, 14, EOT and 90 after randomization in&#xD;
           cloxacillin treatment group versus cloxacillin and fosfomycin treatment group.&#xD;
&#xD;
        -  To evaluate persistent bacteremia (at least one positive blood culture) at day 3 and&#xD;
           persistent bacteremia at day 7 after randomization in the two arms of treatment.&#xD;
&#xD;
        -  To determine the microbiological relapse as defined by at least one positive blood&#xD;
           culture for MSSA at least 72 hours after a preceding negative culture in the two arms of&#xD;
           treatment.&#xD;
&#xD;
        -  To evaluate microbiological treatment failure as defined by positive sterile site&#xD;
           culture for MSSA at least 14 days after randomisation in the two arms.&#xD;
&#xD;
        -  To determine the number of patients with persistent and relapsing bacteremia in the two&#xD;
           arms of treatment.&#xD;
&#xD;
        -  To evaluate the number of patients with complicated bacteremia, defined by persistent&#xD;
           bacteremia, endocarditis or metastatic emboli, prosthetic devices) in the two arms of&#xD;
           treatment.&#xD;
&#xD;
        -  To determine the length of stay in intensive care unit and in hospital in both arms of&#xD;
           treatment.&#xD;
&#xD;
        -  Duration of intravenous antibiotic treatment. Sub group analysis for patients at high&#xD;
           risk (persistent bacteraemia, metastatic infection, unknown focus of bacteraemia,&#xD;
           endocarditis, pneumonia).&#xD;
&#xD;
      Microbiological secondary endpoints:&#xD;
&#xD;
        -  To determine emergency of fosfomycin-resistant strains during therapy in the arm of&#xD;
           combination treatment.&#xD;
&#xD;
        -  To evaluate operon agr functionality and its relationship with Minimum Inhibitory&#xD;
           Concentration (MIC) changes to vancomycin (VAN) and daptomycin (DAP) and with biofilm&#xD;
           production.&#xD;
&#xD;
        -  To analyze VAN and DAP MIC as markers of complications during bacteraemia.&#xD;
&#xD;
        -  To determine the &quot;in vitro&quot; cloxacillin plus fosfomycin combination synergy.&#xD;
&#xD;
        -  To realize whole genome sequencing and its changes in patients with treatment failure.&#xD;
&#xD;
      Pharmacological secondary endpoints:&#xD;
&#xD;
        -  To determine minimum and maximum concentration in steady state of fosfomycin and&#xD;
           cloxacillin.&#xD;
&#xD;
        -  To evaluate pharmacokinetic variability of these concentration.&#xD;
&#xD;
        -  To study the association between PK parameters and efficacy.&#xD;
&#xD;
      Security secondary endpoints:&#xD;
&#xD;
      To evaluate the security of cloxacillin and fosfomycin combination compared with cloxacillin&#xD;
      monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success at day 7</measure>
    <time_frame>Day 7 after randomization.</time_frame>
    <description>Composite endpoint defined by all of the following criteria met after randomization: patient alive at day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever resolved at day 7 AND negative blood cultures for S. aureus at day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success at TOC</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>In case of achieving statistical differences in the primary endpoint, we will perform a hierarchical analysis of the treatment success at Test of Cure visit (TOC, 12 weeks after randomisation).&#xD;
Treatment success at TOC visit, defined by presence of all of the following:&#xD;
Patient alive at TOC;&#xD;
No isolation of MSSA in blood culture or in another sterile site from day 8 until TOC.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Methicillin Susceptible Staphylococcus Aureus Septicemia</condition>
  <arm_group>
    <arm_group_label>Combination therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy group</intervention_name>
    <description>Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.</description>
    <arm_group_label>Combination therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy group</intervention_name>
    <description>Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.</description>
    <arm_group_label>Standard therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects, aged ≥ 18 years;&#xD;
&#xD;
          -  MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to&#xD;
             randomisation in patients with clinical suspicion of infection;&#xD;
&#xD;
          -  Written informed consent of the participant or the legal representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe clinical status with expected death &lt;48h.&#xD;
&#xD;
          -  Severe hepatic cirrhosis (Child-Pugh C).&#xD;
&#xD;
          -  Moderate-severe cardiac chronic failure (NYHA III-IV).&#xD;
&#xD;
          -  Prosthetic endocarditis (need for concomitant antibiotic therapy active against S.&#xD;
             aureus together with the study antibiotics for the first 7 days of the study).&#xD;
&#xD;
          -  No pre-existing evidence of S. aureus fosfomycin non-susceptibility.&#xD;
&#xD;
          -  Known hypersensitivity to cloxacillin or fosfomycin.&#xD;
&#xD;
          -  Polymicrobial bacteraemia with more than one microorganism in blood cultures.&#xD;
&#xD;
          -  A positive pregnancy test or pregnancy or lactation at the time of inclusion.&#xD;
&#xD;
          -  Miastenia gravis.&#xD;
&#xD;
          -  Participation in another clinical trial.&#xD;
&#xD;
          -  Previous participation in the present clinical trial.&#xD;
&#xD;
          -  Acute SARS-CoV2 infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Pujol Rojo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Grillo, MD</last_name>
    <phone>0034 932 60 75 00</phone>
    <email>sarris.grillo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miquel Pujol Rojo, Md, PhD</last_name>
    <email>mpujol@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lluisa Pedro Botet</last_name>
      <email>mlpbotet.germanstrias@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí Moisés Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Oriol, MD, PhD</last_name>
      <email>Isabel.OriolBermudez@sanitatintegral.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cruces</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gorane Euba</last_name>
      <email>EUBAUGARTE@Osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Pujol Rojo</last_name>
    </contact>
    <investigator>
      <last_name>Sara Grillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Gomez-Zorrilla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Morata</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Lopez Contreras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Jover</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lucus Agustí</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria José García País</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Gioia</last_name>
      <email>francesca_gioia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Sanjuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Sant Joan</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Iftimie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Gasch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Eduardo López-Cortés</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graciano García Pardo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Mùtua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Boix</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Ramón Paño Pardo</last_name>
      <email>jrpanno@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bergin SP, Holland TL, Fowler VG Jr, Tong SYC. Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus. Curr Top Microbiol Immunol. 2017;409:263-296. doi: 10.1007/82_2015_5001.</citation>
    <PMID>26659121</PMID>
  </reference>
  <reference>
    <citation>van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11. Review.</citation>
    <PMID>22491776</PMID>
  </reference>
  <reference>
    <citation>Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MA, Benito N, Rodriguez-Baño J, Espejo E, Pujol M; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013 Nov;19(11):1049-57. doi: 10.1111/1469-0691.12108. Epub 2013 Jan 17.</citation>
    <PMID>23331461</PMID>
  </reference>
  <reference>
    <citation>Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, Nieberg P, Spellberg B, Wong-Beringer A. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis. 2020 Feb 3;70(4):566-573. doi: 10.1093/cid/ciz257.</citation>
    <PMID>30949675</PMID>
  </reference>
  <reference>
    <citation>Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Domínguez MÁ, Gasch O, Lora-Tamayo J, Miró JM, Palomar M, Pascual A, Pericas JM, Pujol M, Rodríguez-Baño J, Shaw E, Soriano A, Vallés J. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015 Nov;33(9):625.e1-625.e23. doi: 10.1016/j.eimc.2015.03.015. Epub 2015 May 1.</citation>
    <PMID>25937457</PMID>
  </reference>
  <reference>
    <citation>Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG). Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14.</citation>
    <PMID>29249276</PMID>
  </reference>
  <reference>
    <citation>Grillo S, Cuervo G, Carratalà J, Grau I, Pallarès N, Tebé C, Guillem Tió L, Murillo O, Ardanuy C, Domínguez MA, Shaw E, Gudiol C, Pujol M. Impact of β-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019 Oct 15;69(9):1480-1488. doi: 10.1093/cid/ciz018.</citation>
    <PMID>30615122</PMID>
  </reference>
  <reference>
    <citation>Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017 Jun;23(6):363-372. doi: 10.1016/j.cmi.2016.12.005. Epub 2016 Dec 9. Review.</citation>
    <PMID>27956267</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miquel Pujol</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing of data generated by this project is an essential part of our proposed activities and will be carried out in several different ways. We would wish to make our results available both to the community of scientists interested in infectious diseases and the biology of Staphylococcus aureus to avoid unintentional duplication of research.&#xD;
The preliminary results will be presented at international and national infectious diseases conferences and will be published in peer-reviewed journals. The results will also be made available through press and social media communications. Any formal presentation or publication of data collected from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the ICMJE. Individual participant data that underlie the results, after deidentification will be available. Proposals should be directed to the corresponding author.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>immediately following publication and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with researchers who provide a methodologically sound proposal to achieve aims in the approved proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

